Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

Share Price is delayed by 15 minutes
Get Live Data
331.50    0.00 (0.00%)
Bid:
330.00
Ask:
333.00
Spread: 3.00 (0.909%)
Market Cap: £228.89m
ANCR Live PriceLast checked at - London Stock Exchange

Intraday Animalcare Grp Share Chart

Form 8.5 (EPT/RI)

24 Jun 2026 10:38

RNS Number : 5869J
Panmure Liberum Limited
24 June 2026
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Liberum Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Animalcare Group plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Animalcare Group plc

(d) Date dealing undertaken:

23 Jun 2026

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

20p ordinary

Purchase

3,514

3.32351 GBP

3.3233 GBP

20p ordinary

Sales

25,000

3.325 GBP

3.325 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

24/06/2026

Contact name:

Shivani Ghiraiya

Telephone number:

+44 (0) 20 3100 2213

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERFZGZVLDVGVZG
Date   Source Headline
28th Sep 20217:00 amRNSInterim Results H1 2021
16th Sep 202110:46 amRNSNotification of Major Holding
9th Sep 20211:44 pmRNSNotification of Major Holding
2nd Aug 20217:00 amRNSNotification of Total Voting Rights
30th Jul 202112:00 pmRNSNotification of Major Holding
22nd Jul 20217:00 amRNSHalf Year Trading Update and Notice of Results
15th Jul 20214:11 pmRNSNotification of Major Holding
15th Jul 20217:00 amRNSDirector/PDMR Notification
12th Jul 20214:15 pmRNSNotification of Major Holding
12th Jul 20214:00 pmRNSNotification of Major Holding
12th Jul 20213:35 pmRNSNotification of Major Holding
12th Jul 202111:04 amRNSNotification of Major Holding
12th Jul 20217:00 amRNSExercise of options
9th Jul 20214:59 pmRNSNotification of Major Holding
9th Jul 20213:20 pmRNSNotification of Major Holding
8th Jul 20215:45 pmRNSResult of Secondary Placing
8th Jul 20214:41 pmRNSSecond Price Monitoring Extn
8th Jul 20214:35 pmRNSPrice Monitoring Extension
8th Jul 20212:06 pmRNSSecond Price Monitoring Extn
8th Jul 20212:00 pmRNSPrice Monitoring Extension
8th Jul 20211:00 pmRNSProposed Secondary Placing
1st Jul 20217:00 amRNSTotal Voting Rights
21st Jun 20217:00 amRNSExercise of options
17th Jun 202110:17 amRNSDirector/PDMR Notification
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20215:03 pmRNSResult of 2021 AGM
17th May 20217:00 amRNSAnnual Report 2020 and Notice of AGM
22nd Apr 20217:00 amRNSDaxocox approved by EU and UK authorities
30th Mar 20217:00 amRNSFull Year Results 2020
23rd Mar 20217:00 amRNSNotification of major holding
18th Feb 20214:36 pmRNSPrice Monitoring Extension
18th Feb 20213:43 pmRNSDaxocox receives positive opinion from CVMP in EU
8th Feb 20212:46 pmRNSNotification of major holding
1st Feb 20217:00 amRNSAppointment of Nominated Advisor and Joint Broker
21st Jan 20217:00 amRNSTrading Update and Notice of Full Year Results
18th Nov 20207:00 amRNSGrant of options
29th Sep 20207:00 amRNSInterim Results H1 2020
28th Sep 20207:00 amRNSAnimalcare and Kane Biotech to target biofilms
23rd Jul 20207:00 amRNSTrading Update and Notice of Results
30th Jun 20204:00 pmRNSResult of AGM 2020
9th Jun 20203:55 pmRNS2019 Annual Report and Notice of 2020 AGM
28th May 20207:00 amRNSFull year results 2019
18th May 202011:20 amRNSNotice of Full Year 2019 Results
25th Mar 20207:00 amRNSTrading update, revised date for full year results
23rd Jan 20207:00 amRNSTrading Update & Notice of Results
17th Jan 20208:55 amRNSHoldings in Company
24th Sep 20197:00 amRNSHalf Year Results
25th Jul 20197:00 amRNSDirectorate Change
23rd Jul 20197:00 amRNSTrading Update & Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.